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ABSTRACT
Despite the fact that Parkinson’s disease (PD) is the second most common 
neurodegenerative disease, much of its etiology and pathogenesis remains to be 
discovered. The main pathological feature of PD is the progressive death o f specific 
dopaminergic (DAergic) neurons in the brain. Oxidative stress induced cell death has 
been hypothesized as one mechanism responsible for PD pathogenesis.
Hydrogen peroxide (H2O2) is a reactive oxygen species (ROS) that has been 
implicated in PD as a by-product of dopamine (DA) degradation. 1 -methyl-4-phenyl- 
1,2,3,6-tetrahydropyridine (MPTP) has been shown to produce a Parkinsonian 
syndrome via an oxidative stress induced mechanism. For these reasons, H2 O2 and 
MPTP were used in this study to treat DAergic PC 12 cells to produce a model o f PD.
We hypothesized that (-)-epigallocatechin 3-O-gallate (EGCG), a principal 
chemical component of green tea known for a plethora of health promoting bioactive 
properties, protects PC 12 cells from H2O2- and MPTP-induced stress.
PC 12 cells treated with EGCG showed increased cell count when compared to 
untreated cells or cells only treated with H2O2 or MPTP. Cell count increased as EGCG 
concentration increased.
The results of this study demonstrate that EGCG has neuroprotective effects on 
H2O2 and MPTP stressed PC 12 cells.
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Introduction
Parkinson’s Disease (PD)
PD is the second most common neurodegenerative disorder after Alzheimer’s disease 
(reviewed in (Bove et al. 2005, Danielson and Andersen 2008, Dauer and Przedborski 
2003). In the United States alone, there are over one million cases of PD (reviewed in 
(Drechsel and Patel 2008)), with approximately 50,000 new diagnoses each year 
(reviewed in (Bove et al. 2005)). While genetic mutations in several proteins, including 
a-synuclein, LRRK1 and others, have been found to cause PD, the majority of PD cases 
occur sporadically (reviewed in (Cali et al. 2011, Lotharius and Brundin 2002)). The 
etiology of sporadic PD remains unknown (reviewed in (Deumens et al. 2002, Hald and 
Lotharius 2005)). The hallmark clinical symptoms of PD include bradykinesia, resting 
tremor, rigidity and postural instability, and in some cases, dementia (reviewed in 
(Drechsel and Patel 2008, Exner et al. 2012, Mosley et al. 2006)). These symptoms are 
the result of the progressive loss of DAergic neurons, particularly those found in the 
substantia nigra pars compacta (reviewed in (Danielson and Andersen 2008, Drechsel and 
Patel 2008, Hastings 2009)). For yet unknown reasons, the DAergic neuron population in 
the substantia nigra pars compacta show particular susceptibility in comparison to those 
in the ventral tegmental region of the brain (reviewed in (Przedborski et al. 2001)). The 
loss of these neurons leads to decreased levels of DA in the striatum, which is responsible 
for movement control (reviewed in (Dauer and Przedborski 2003, Drechsel and Patel 
2008)). Symptoms are not typically observed in a PD patient until 60 to 70% of the 
DAergic neurons have already been lost and over 80% of DA levels have been depleted 
(reviewed in (Deumens et al. 2002, Drechsel and Patel 2008, Hald and Lotharius 2005,
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Schulz and Falkenburger 2004)). For these reasons, further research is required to 
establish the cause o f PD and discover ways to prevent the initiation and progression of 
the disease.
PD Treatment
Currently, treatment is limited to treating the symptoms of the disease, not the underlying 
cause of the disease; the most common treatment for PD is levodopa (L-DOPA)
(reviewed in (Bargiotas and Konitsiotis 2013)). L-DOPA, a precursor to DA, is able to 
cross the blood brain barrier into the brain, where it is converted to DA in neurons (Gey 
and Pletscher 1964). The purpose of treatment with L-DOPA is to elevate DA levels in 
the brain; however, as the population of neurons responsible for converting L-DOPA is 
declining in PD, and as DA itself could contribute to the pathology of PD, L-DOPA is not 
a very effective treatment in the long term (reviewed in (Miyazaki and Asanuma 2008)). 
Furthermore, chronic treatment with L-DOPA leads to adverse effects including a 
number of deficits in motor response such as L-DOPA induced dyskinesia, hallucinations 
and other symptoms, in addition to the PD symptoms already present (reviewed in 
(Bargiotas and Konitsiotis 2013, Miyazaki and Asanuma 2008)). While L-DOPA is the 
most effective treatment currently for relieving PD symptoms, it cannot halt the 
progression of the disease (reviewed in (Bargiotas and Konitsiotis 2013)). The limitations 
in current treatment advocate the importance of further elucidating the mechanisms 
underlying the progression of PD; therefore, more successful ways to treat PD and to stop 
its progression must still be discovered.
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Reactive Oxygen Species (ROS) in PD
While the initial cause of the disease remains unknown, several hypotheses point to a 
number of mechanisms of specific oxidative stress in which elevated production of ROS 
results in cellular damage of extracellular and intracellular components and ultimately 
leads to cell death of DAergic neurons in the nigrostriatal pathway (reviewed in (Drechsel 
and Patel 2008, Hald and Lotharius 2005, Mosley et al. 2006, Sherer et al. 2002)). The 
production of ROS is a normal physiological occurrence and ROS are usually 
enzymatically converted to harmless molecules such as water (reviewed in (Mosley et al. 
2006)). However, in diseases such as PD, increased levels of ROS overwhelm normal 
degradation mechanisms and cause damage of cellular components, which ultimately 
leads to cell death (reviewed in (Mosley et al. 2006)). In PD, the DAergic neurons are 
particularly susceptible to oxidative stress as DA metabolism results in various toxic 
species including hydrogen peroxide (H2O2) (reviewed in (Drechsel and Patel 2008, 
Lotharius and Brundin 2002)). The degradation of DA by monoamine oxidase A (MAO- 
A) and the auto-oxidation of dopamine were shown to be coupled with the production of 
endogenous H2O2 (reviewed in (Hald and Lotharius 2005)). As DA accumulates in the 
cytosol, it is prone to undergo auto-degradation and enzymatic degradation (reviewed in 
(Lotharius and Brundin 2002)). A product of DA degradation, dopamine-quinone 
(reviewed in (Asanuma et al. 2004) (Hald and Lotharius 2005)), also inhibits complex I 
in the mitochondrial electron transport chain (reviewed in (Hald and Lotharius 2005, 
Lotharius and Brundin 2002)). Complex I is responsible for pumping protons across the 
mitochondrial membrane to create a concentration gradient, and when this process is 
inhibited, there are more electrons available for the production o f superoxide and other
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ROS (reviewed in (Cali et al. 2011)). Mitochondrial damage is also found in glial cells in 
the PD brain(Schmidt et al. 2011). Thus, DA itself may contribute to oxidative stress 
induced cell death implicated in PD by two mechanisms, DA degradation and inhibition 
of the mitochondrial electron transport chain (reviewed in (Drechsel and Patel 2008, Hald 
and Lotharius 2005)). Studies have also shown an increase in exogenous ROS resulting 
from an inflammatory response by proximal microglia (Wu et al. 2003).
PC 12 cells as a PD model
PC 12 cell line was developed from a rat adrenal pheochromocytoma as a way to study 
the nervous system at a single cell and multi-cell level; norepinephrine and DA are 
predominant catecholamines found in these cells (Greene and Tischler 1976). MAO is 
also found in PC 12 cells and is responsible for the enzymatic degradation of 
catecholamines (Greene and Tischler 1976). For these reasons, PC 12 cells are widely 
used as a model for PD when treated with toxins that reproduce PD symptoms such as 6- 
OHDA, MPTP, H2O2, and rotenone (Fonck and Baudry 2001, Grau and Greene 2012, Lu 
et al. 2010, Snitsarev et al. 2013, Thakur and Nehru 2014).
1 -Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)
In the 1980s, drug users developed a Parkinsonian syndrome after an intravenous 
injection of synthetic opioid-like drugs traced with MPTP, a by-product of illicit drug 
synthesis (Langston et al. 1983, Langston et al. 1999). Since MPTP was found to induce 
many of the clinical symptoms associated with PD in humans, it has been widely used as 
a toxin to create PD models (Chiba et al. 1984). MPTP is highly lipophilic and as such, is 
able to readily cross the blood brain barrier to the brain where it is converted into the 
active metabolite 1 -methyl-4-phenylpyridine (MPP+) by the enzyme MAO-B in non-
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DAergic glial cells (reviewed in (Dauer and Przedborski 2003)). MPP+ is taken up via the 
DA transporter into DAergic neurons where it acts as a potent neurotoxin (reviewed in 
(Cali et al. 2011, Dauer and Przedborski 2003)). In DAergic neurons, MPP+ inhibits 
complex I of the electron transport chain, resulting in the increased production of ROS 
(reviewed in (Bove et al. 2005, Dauer and Przedborski 2003)). When MPP+ utilizes the 
DA transporter, it causes displacement of DA into the cytosol, where it is more readily 
degraded and produces ROS (reviewed in (Lotharius and Brundin 2002)). MPTP 
specifically damages DAergic neurons in the nigrastriatal pathway (Langston et al. 1999), 
thus reproducing clinical and pathological aspects o f PD (reviewed in (Bove et al. 2005, 
Dauer and Przedborski 2003)).
(-)-Epigallocatechin 3-O-gallate (EGCG)
After water, tea is the second most consumed beverage around the world (reviewed in 
(Kanwar et al. 2012, Steinmann et al. 2013)). Catechins are the main components of 
green tea with EGCG constituting approximately 59% of the total catechins content 
(reviewed in (Steinmann et al. 2013)). In addition to its established antiviral, antibacterial 
and antifungal effects, EGCG has also been shown to have various beneficial effects at 
the cellular level (reviewed (Steinmann et al. 2013)). Studies have established the 
anticancerous effects o f EGCG (reviewed in (Yang C. S. et al. 2002)) including its ability 
to inhibit growth by reducing oncogene expression, increasing expression of tumor 
suppressor genes and inhibiting telomerase (reviewed in (Chen et al. 2011, Kanwar et al. 
2012)). In the 6-hydroxy dopamine (6-OHDA) treated rat model of PD, EGCG was found 
to protect DAergic neurons through inhibition of the ROS-NO pathway, which is 
implicated in 6-OHDA induced cell death and in PD neuronal death (Guo et al. 2007).
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Hypothesis
EGCG protects PC 12 cells from H2O2- and MPTP-induced stress.
Materials and Methods
PCI 2 cells
PC 12 cells were cultured similar to (Yermolaieva et al. 2000) (Yermolaieva et al. 2004). 
Briefly, PC 12 cells were plated at 104 cells/cm2 in 60 (35 mm) Petri dishes in 2.5 mL of 
the DMEM culture medium supplemented with 10% horse serum, 5% fetal bovine serum, 
1% L-Glutamine, and 0.5% Pen/Strep (Life Technologies, Carlsbad, CA). PC 12 cells 
were used at a passage less than thirty. Five wells were used as a control with no 
treatment. Five wells were treated with varying EGCG concentrations, 10' M, 10' M, 
and 10'6 M. Five wells were treated only with 10'4 M H2O2. 15 wells were treated with 10'
4 M H2O2 and different concentrations of EGCG: five with 10'8 M, five with 10'7 M and 
five with 10'6 M. Five wells were treated only with 10'5 M MPTP. 15 wells were treated 
with 10'5 M MPTP and different concentrations of EGCG, five with 10‘8 M, five with 10'7 
M and five with 10'6 M. EGCG was applied 5 min after the toxin treatment. The PC 12 
cells with respective treatments were incubated for 24 hours in 5% CC>2/95% air at 37°C.
PCI 2 cells images
Four bright field pictures were taken of each 35 mm Petri dish using a Nikon Eclipse TI-
5 Microscope (Nikon Instruments Inc., Melville, NY) and Photometries CoolSnap EZ 
camera (Photometries, Tucson, AZ) at an objective of 20x at random locations on the 
plate. Each picture encompassed a rectangular space of 670 pm by 900 pm for a total
area of 603 mm (Fig. 1, upper panels). The number of cells in each image was counted 
manually.
Statistical analysis
The mean, standard error of the mean (SEM) and p-values were calculated in Excel 
(Microsoft Office, Microsoft, Redmond, Washington, USA). The p-values were 
calculated with a student t-test for a two-tail distribution and two-sample unequal 
variance. P-values less than 0.05 are considered significant.
Chemicals
EGCG, MPTP and H2O2 were purchased from Sigma-Aldrich (St. Louis, MO).
PC 12 were purchased from the American Type Culture Collection (Manassas, VA).
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Results
Control (no H2O2 or MPTP treatment)
Fig. 1 shows representative images of the cells for each treatment. A visual observation 
of the images indicates that cells treated with EGCG show increased cell count. Petri 
dishes treated with higher concentrations of EGCG show higher cell counts. In cells 
treated with EGCG in concentrations of 1 O'8 M, 10~7 M and 10"6 M, average cell count 
significantly increased by 1.6 fold, 1.6 fold and 2.6 fold, respectively, from untreated 
cells (Fig. 2A, Table 1)
H2O2 treatment
Treatment of PC 12 cells with H2O2 (KF4 M) resulted in 68% ± 3%  (SEM) cell death 
during 24 hours. Fig. IB shows the decrease in cell count compared to the cell count seen 
in Fig. 1 A, Control. Visual observation of the images indicates that cells treated with 
H2O2 (10'4 M) and increasing concentrations of EGCG showed increased cell count 
compared to cells treated only with H2O2. For cells treated with H2O2 and 10' M EGCG, 
10'7 M EGCG and 10‘6 M EGCG, average cell count significantly increased in a dose- 
dependent manner by 1.4 fold, 4.0 fold and 6.7 fold, respectively (Fig. 2A, Table 2).
Cells treated with H2O2 and 10"7 M EGCG showed no significant difference in average 
cell number from untreated cells. Cells treated with H2O2 and 10'6 M EGCG showed a 
significant increase in cell count compared to untreated cells (Table 1).
MPTP treatment
Treatment of PC 12 cells with MPTP (10"5 M) resulted in 44% ± 4% (SEM) cell death 
during 24 hours. The difference in cell count between control and MPTP treated cells can
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be seen in a comparison of Fig. 1A and Fig. 1C. Visual observation of the images in Fig.
1C indicates that increasing the concentration of EGCG results in increasing cell counts. 
In cells treated with MPTP and 1 O'8 M EGCG, 1 O'7 M EGCG and 10"6 M EGCG, average 
cell count significantly increased by 1.5 fold, 2.2 fold and 4.1 fold, respectively (Fig. 2A, 
Table 2). Cells treated with MPTP and 10'7 M EGCG showed no significant difference in 
average cell number from untreated cells. Cells treated with MPTP and 10‘6 M EGCG 
showed a significant increase in cell count compared to untreated cells (Table 1).
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Control EGCG 10 * M EGCG 10 7 M EGCG IO 4 M
MPTP MPTP ♦ EGCG 10 * M MPTP ♦ EGCG 10 7 M MPTP + EGCG 10 * M
Figure 1. Representative images of each cell treatment.
A. Control and treatment with EGGC in varying concentrations.
B. Cells treated with H2O2 (10'4M) and varying concentrations o f EGCG.
C. Cells treated with MPTP (10~5 M) and varying concentrations of EGCG.
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Figure 2. Comparisons between different cell treatments. The number of cells per image 
frame for each cell treatment. Average values ± SEM are shown.
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Table 1. Cell number for each cell treatment and the p-value when compared to the non-
treated cells. Average values are shown ± SEM.
Cell Number P-Value
Control 82.6 ±5.6 —
EGCG IO'8 M 135.7 ±8.4 < 0.001
EGCG IO'7 M 131.3 ±9.0 < 0.001
EGCG IO'6 M 214.2 ±25.2 < 0.001
h2o 2 23.8 ± 1.6 < 0.001
H20 2 + EGCG IO'7 M 94.1 ± 10.2 0.327
H20 2 + EGCG IO'6 M 159.9 ± 14.6 < 0.001
MPTP 44.05 ± 2.9 < 0.001
MPTP + EGCG 10'8 M 65.7 ±5.9 0.044
MPTP + EGCG 10'7 M 97.2 ±6.8 0.106
MPTP + EGCG 10'6 M 180.0 ±19.1 < 0.001
Table 2. Cell number for each treatment with H2O2 and MPTP and the p-value of each 
treatment with EGCG compared to treatment only with the toxins. Average values are 
shown ± SEM.
H20 2 (23.8 ± 1.6) MPTP (44.05 ±2.9)
Mean P-Value Mean P-Value
EGCG 10 8 M 33.3 ±2.7 0.005 65.7 ±5.9 0.002
EGCG IO 7 M 94.1 ± 10.2 < 0.001 97.2 ± 6.8 < 0.001
EGCG IO'6 M 159.9 ± 14.6 < 0.001 180.0 ± 19.1 < 0.001
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Discussion
Effects o f  EGCG on PC 12 cells growth
For these experiments, 10'8 M, 10"7 M and 10’6 M EGCG were used because peak plasma 
levels of EGCG in humans after typical green tea consumption were found to be between 
approximately 10'7 M and 10"6 M (Chow et al. 2003, Lee et al. 2002). When compared to 
untreated cells, increasing the concentration of EGCG resulted in an increasing number 
of cells in culture (Fig.lA  and 2). This observation indicates that EGCG is not cytotoxic 
at these concentrations. Cells in culture can only grow to a certain extent due to 
restrictions on the size of the plate and the availability of nutrients. EGCG allowed for 
more cells to survive in a limited space, possibly by reducing the harmful effects of 
endogenously produced ROS that could otherwise inhibit cell proliferation in culture. In 
this study, the observed beneficial effect of EGCG in micromolar and submicromolar 
concentrations on the growth of PC 12 cells, a cancerous cell line, contradicts the widely 
reviewed anticancerous effects of green tea consumption in humans (Chen et al. 2011, 
Kanwar et al. 2012). In cancer cell lines, the cytotoxic effects of EGCG are observed for 
concentrations of EGCG at 10 pM and higher (Noguchi et al. 2006, Qiao et al. 2009,
-8Spinella et al. 2006), significantly exceeding the concentrations used in this study (10' M, 
10'7 M and 10'6 M) as well as the levels of EGCG found in human plasma after typical 
consumption of green tea, between approximately 10'7 M and 10"6 M (Chow et al. 2003, 
Lee et al. 2002). It is also possible that EGCG has cell specific effects, and whether it will 
promote cell survival or induce apoptosis is dependent on the particular cell type or status 
(Yamamoto et al. 2003). Further research into this apparent inconsistency is necessary.
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Previous Studies with PC I2 cells and EGCG
Previous studies using PC 12 cells and EGCG have produced inconsistent results. While 
some have indicated that EGCG has no protective effects in PC 12 cells and may worsen 
the effects stressors have on cells or induce apoptosis (Crispo et al. 2010a, Crispo et al. 
2010b, Mazzio et al. 2001, Raza and John 2005, 2008), others suggest that EGCG does 
protect against oxidative stress (Flueraru et al. 2005, Koh et al. 2003, Srividhya and 
Kalaiselvi 2013, Ye et al. 2012).
Not all the investigators found that EGCG protected PC 12 cells against the effects of 
MPTP toxicity, as is evident in Mazzio et al.’s study (Mazzio et al. 2001). This study 
used a population of PC 12 cells that had evolved from the original cell line. In this 
evolution process, they may have also mutated to resist the effects of EGCG. In our study, 
PC 12 cells were used and not a line that had evolved from PC 12 cells.
In the Crispo et al. study, Protective effects o f methyl gallate on H202-induced apoptosis 
in PCI2 cells, it was determined that EGCG exacerbates the stress caused by H2O2. 
However, a higher concentration (10 pM) of EGCG was used than that which was used in 
our study (Crispo et al. 2010b). Higher concentrations of EGCG (greater than 10'5 M) are 
potentially cytotoxic (Raza and John 2005). Crispo et al.’s study, Protective effects o f 
polyphenolic compounds on oxidative stress-induced cytotoxicity in PCI2 cells, EGCG 
showed no rescue effect on PC 12 cells treated with H2O2. 10-4 M EGCG was also used, 
which is again, a higher concentration of EGCG than used in this study and higher than 
that which is found in the body after green tea consumption (Crispo et al. 2010a).
A range o f concentrations of EGCG were used for the Flueraru et al. study. When cells 
were treated solely with EGCG, increasing concentrations of EGCG to greater than 10'4
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M resulted in higher cytotoxicity. However, when cells were treated with 2,2’-azobis(2- 
amidinopropane) hydrochloride (AAPH) to induce oxidative stress, lower concentrations 
of EGCG were used (approximately 10"5 M) and the cells were protected against 
oxidative stress induced cell death. This concentration of EGCG is higher than the one 
which was used in our study, but it showed similar results. One thing to consider in this 
study is that the cells were pretreated with EGCG. Thus, the results may not be accurate 
as EGCG may have neutralized AAPH before it reached the cell (Flueraru et al. 2005, 
Kondo et al. 1999).
Surprising, the Koh et al. study shows that increasing EGCG concentrations up to 200 
pM results in increased cell viability and decreased apoptosis. This is a much greater 
concentration of EGCG than what was used in our study. However, the cells were 
pretreated with EGCG. While the paper notes that the wells were washed before addition 
of H2O2, the possibility remains that EGCG neutralized H2O2 within the cells due to the 
scavenging effects of EGCG. Thus, while these results appear inconsistent with the rest 
o f the studies in that such high concentrations of EGCG result in increased cell viability; 
this could be result o f EGCG scavenging before H2O2 has damaged the cell (Koh et al. 
2003, Kondo et al. 1999).
Raza and John’s 2005 study shows that increasing the concentration of EGCG in PC 12 
cells causes the increased production of ROS. However at 10'5 M, no significant increase 
was seen. It is concluded that at lower concentrations, such as the ones we used in our 
study, EGCG acts as an antioxidant. They also determined that EGCG has differential 
effects in various cellular compartments (Raza and John 2005).
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Raza and John’s 2008 study showed that using 10'4 M EGCG, a higher concentration that 
which was used in our study, resulted in the decreased production of ROS in PC 12 cells 
and an increase in apoptosis. While this appears to contradict their previous study, the PC 
12 cells in this study were stressed using 4-HNE whereas the PC 12 cells used in the 
previous study were unstressed. Even though a decrease in the production of ROS is 
observed, apoptosis is still increased which supports the idea that higher concentrations 
of EGCG are cytotoxic (Raza and John 2008).
In the study performed by Srividhya et al., cells were not pretreated with EGCG thus 
eliminating some of the potential scavenging effects. 20 pM of EGCG were used, which 
is higher than the concentrations used in our study but less than the studies where 
apoptosis was induced by EGCG (Srividhya and Kalaiselvi 2013). Similarly, Ye et al.’s 
study did not treat the cells with EGCG before treating with MPP+. The highest 
concentration of EGCG used was 10‘5 M and the cells were protected against stress (Ye 
et al. 2012). These results are similar to the ones observed in our study.
In summary, from a review of these studies, it appears that concentrations greater than 1 O' 
5 M EGCG result in apoptosis while concentrations less than 10"5 M EGCG have 
antioxidant and protective effects in cells. For our study, we used concentrations of 
EGCG between 10'8 M and 10'6 M, as these are the concentrations found in blood plasma 
levels after typical green tea consumption. These concentrations of EGCG are not toxic 
and have protective effects against stressors. Also, in our study, cells were treated with 
EGCG after being treated with the toxins. Our results suggest that EGCG can repair 
damage previously inflicted by MPTP and H2O2.
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EGCG protects PC 12 cells from H2O2 and MPTP-induced damage 
The other groups o f cells were treated with 10’4 M of H2O2 or 10'5 M MPTP (Fig. IB, 1C 
and 2). H2O2 is implicated in the pathogenesis of PD as a byproduct of dopamine 
degradation and a ROS (reviewed in (Danielson and Andersen 2008)). We applied 10'4 M 
of H2O2 because this concentration of H2O2 caused about 50% or greater cell death in 
PC 12 cells (Jiang et al. 2007, Lu et al. 2010). MPTP has been developed as a stressor to 
replicate PD symptoms, as it follows a similar pathway in causing oxidative stress 
induced cell death by inhibiting complex I of the mitochondrial electron transport chain 
(reviewed in (Chung et al. 2005, Danielson and Andersen 2008, Drechsel and Patel 
2008)). We applied 10° M of MPTP because this concentration of MPTP caused about 40% 
death or greater in PC12 cells (Hracsko et al. 2011, Yang S. F. et al. 2001). Compared to 
untreated colonies, cell count was significantly decreased in cells treated with H2O2 (Fig.
1 and 2A, Table 1) or MPTP (Fig. 1 and 2A, Table 1), indicating that H2O2 and MPTP 
can cause cell death. When these groups o f cells were also treated with different 
concentrations of EGCG, there was a significant increase in the number o f cells in each 
sample (Fig. IB, 1C and 2A). Cell count increased in a dose-dependent manner. Cells 
treated with H2O2 or MPTP and 10'7 M EGCG showed no significant difference in 
average cell number compared to untreated cells. This would appear to indicate that this 
treatment of EGCG was able to increase cell count to a similar cell count observed in 
non-PD. Cells treated with H2O2 or MPTP and 10'6 M EGCG showed significant increase 
in cell count compared to untreated cells. Therefore, the results demonstrate the 
neuroprotective effects o f EGCG on PC 12 cells that are undergoing oxidative stress 
induced cell damage and death.
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Limitations
PC 12 cells as a PD model
While PC 12 cells provide a suitable model for studying PD, future studies should use 
human DA producing neuronal cells to determine if these results can be duplicated in the 
cells actually affected in PD. PC 12 cells are tumor cells, which could impact how EGCG 
affects cellular processes. Also, while the results show that cell count is increased with 
application of EGCG, nothing can be determined about how the transport or storage of 
DA is affected. Any treatment will only be effective if it can increase cell count and 
ensure that DA is being transported effectively.
PC 12 cell images
Taking pictures at four random locations of each well could potentially provide for an 
inaccurate portrayal of the effects of different treatments. Future studies should use 
smaller plate sizes or multiwall clusters that could be totally captured in one image.
PC 12 cells counting
Due to the nature o f PC 12 cell growth, cell counting needed to be done manually. As 
previously stated, this method is not only time consuming be could introduce human error 
into the study. The need for this will have to be eliminated for future studies.
EGCG
Finally, EGCG is unstable and has low bioavailability. EGCG derivatives may prove 
more effective to determine their effectiveness in functioning as a neuroprotective agent 
(Landis-Piwowar et al. 2013).
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